Arch Therapeutics Inc   (ARTH)
Other Ticker:  
Price: $2.9000 $-0.08 -2.685%
Day's High: $2.94 Week Perf: -4.61 %
Day's Low: $ 2.90 30 Day Perf: -45.79 %
Volume (M): 0 52 Wk High: $ 18.00
Volume (M$): $ 1 52 Wk Avg: $3.21
Open: $2.94 52 Wk Low: $0.39

 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Arch Therapeutics Inc
Arch Therapeutics Inc. is a medical device company that focuses on developing innovative technologies to control bleeding and fluid loss during surgical and medical procedures. The company's flagship product is the AC5 Surgical Hemostatic Device, which is a self-assembling peptide scaffold that helps in the management of surgical and traumatic bleeding. Arch Therapeutics aims to provide surgeons with improved hemostatic solutions that are easy to use, effective, and safe. The company is headquartered in Framingham, Massachusetts, and is dedicated to addressing unmet medical needs in the field of surgical hemostasis.

   Company Address: 235 Walnut Street, Suite 6 Framingham 1702 MA
   Company Phone Number: 431-2313   Stock Exchange / Ticker: ARTH


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Arch Therapeutics Inc

ARCH Therapeutics Inc. Shows Strong Revenue Growth in Financial Report Ending Dec 31, 2023

In financial news, Arch Therapeutics Inc (ARTH) reported a significant boost in revenue of 632.583% to $0.05 million for the financial period ending on December 31, 2023. Despite this revenue increase, the company faced a loss of $-0.57 million.
Compared to its industry counterparts in the Medical Equipment & Supplies sector, ARTH has outperformed in terms of revenue growth. The industry as a whole reported a revenue elevation of 5.58% during the same period. In the previous reporting season, ARTH experienced a loss increase from $-0.29 per share, but also saw a revenue improvement of 16.072% to $0.04 million.
For the fiscal interval closing on December 31, 2023, Arch Therapeutics Inc incurred a net loss amounting to $-2.682 million, which is higher than the $-1.800 million loss recorded a year ago. Inventory levels can provide insight into future demand, and in this case, ARTH's inventory declined to $1.3 million compared to the previous quarter and the same period the previous year.

Arch Therapeutics Inc

Arch Therapeutics Inc Surges with Mind-Blowing 112.314% Revenue Growth, Leaving Competitors in the Dust

In the ever-evolving world of the stock market, it's important to stay informed about the latest trends, achievements, and developments. One company that has recently caught the attention of investors is Arch Therapeutics Inc. With a very solid revenue rise of 112.314% year on year, reaching $0.01 million in the April to June 30, 2023 interval, this is certainly something to be excited about.
Arch Therapeutics Inc operates in the Medical Equipment & Supplies sector, and their revenue growth has surpassed that of their industry counterparts. In the third quarter of 2023, while other companies in the sector experienced an average revenue rise of 4.48% from the same period the previous year, Arch Therapeutics Inc soared ahead. This impressive growth is indicative of the company's superior performance and ability to outshine others in the field.

Arch Therapeutics Inc

Arch Therapeutics Inc Discloses a Stunning 98.34% Diminution in Top-Line Results Amidst Q2 2023 Earnings Period; Fiscal Performance Ends Dismally as of March 31, 2023

Arch Therapeutics Inc is a diversified company that operates in the medical technology industry. The company has been in operation for several years, and like most businesses, it has experienced both peaks and valleys in terms of financial performance.
However, the recent announcement of a disastrous fiscal span is quite concerning for investors, employees, and other stakeholders. According to the company's financial statement, the revenue for the fiscal year ending March 31, 2023, decreased by a staggering 98.34% to $0.02 million. In addition, the net deficit per share widened to $-0.71, which represents a significant decline from the previous year.


Arch Therapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Arch Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Arch Therapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com